Blair William & Co. IL Sells 509,462 Shares of DexCom, Inc. (NASDAQ:DXCM)

Blair William & Co. IL decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,232,647 shares of the medical device company’s stock after selling 509,462 shares during the period. Blair William & Co. IL owned 0.57% of DexCom worth $173,633,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc acquired a new position in DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA lifted its stake in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom in the 4th quarter valued at $38,000. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on DXCM shares. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group raised their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Citigroup upped their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Stock Performance

DXCM stock opened at $72.13 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $141.99. The business has a 50-day moving average price of $82.96 and a 200 day moving average price of $77.07. The company has a market capitalization of $28.19 billion, a P/E ratio of 50.44, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.